> > > BOSTON, Aug. 23, 2010 — An unlikely effort is underway to lift the veil of > nearly-total secrecy that has surrounded the process of developing new > prescription drugs for the last century, scientists said today at the 240th > National Meeting of the American Chemical Society (ACS). The upheaval in > traditional practice would make key data available to college students, > university professors, and others in an open, collective process. > > Called open-source drug discovery, the new approach involves an online > community of computer users from around the world working together to > discover and develop much-needed new drugs. It could lead to inexpensive > drugs to treat a wide variety of diseases, including tuberculosis and > malaria, that claim a huge toll in developing countries. > > Scientists from government, industry, and academia are presenting a dozen > reports on this topic during a special symposium entitled "Open-source Drug > Discover" at the ACS meeting. > > Open-source drug discovery is a movement as well as an evolving program. > The Open Source Drug Discovery (OSDD) Consortium, for instance, is a > worldwide scientific community of more than 3000 people from 74 countries > that was launched in 2008 by India's Council of Scientific and Industrial > Research (CSIR), the country's largest research and development > organization. People can participate in the program by logging into a Web > site: www.osdd.net > > "I believe this is the way to go about not only drug discovery, but it may > be a way of doing science in the future," said OSDD Project Director Samir > Brahmachari, Ph.D. "Everybody can contribute." > > Brahmachari, who is director general of CSIR and one of the pioneers of the > open-source movement, notes that most drug discoveries are made in a > closed-door environment in which pharmaceutical companies keep drug > development information under wraps and limit participation of the academic > world, such as colleges and universities. The OSDD program aims to address > this issue by attempting to attract the youngest and brightest minds around > the globe to be part of the drug discovery movement, he said. > > One of the aims of the project is to develop a new drug for tuberculosis, > which kills almost two million people each year worldwide. OSDD recently > announced a step toward this goal by providing a comprehensive map of the > genome of Mycobacterium tuberculosis, the bacterium that causes the disease. > > > "Open-source drug R&D is a broad concept that has many faces," said Michael > Hurrey, Ph.D., program chair of the ACS Division of Business Development and > Management, which is hosting the symposium. He is currently a chemist with > Vertex Pharmaceuticals in Cambridge, Mass. "Our symposium will feature some > of its proudest accomplishments in the hope that some in the audience will > feel emboldened to join the movement and build upon that foundation > > > Press Release > > > > The ACS Division of Business Development and Management (BMGT) is > sponsoring a full day symposium on Open-Source Drug Discovery as part > of the 240th National Meeting of the American Chemical Society. > Speakers include pioneers of the open-source drug discovery movement > who will discuss their first-hand experiences in creating the tools > and platforms that enable the online collaboration of thousands of > scientists working to economically discover and develop much needed > drugs for the treatment of rare and neglected diseases. > > > > Organized by Richard Harper of Indiana University-Purdue University > Indianapolis (IUPUI) and Bernard Munos of Eli Lilly, co-sponsored by > the ACS Division of Medicinal Chemistry and financially sponsored by > Eli Lilly and Company, the OSDD symposium provides an opportunity for > attendees to learn about the present and future of open-source > innovation and hear international practitioners from academia and > industry describe their approaches to setting up and operating open- > source drug R&D programs. > > > > Scheduled for Monday, August 23, 2010 in Room 254A/B of the Boston > Convention & Exhibition Center, the morning session begins at 8:30 > with opening remarks by Harper and Munos followed by presentations > from Dr. Samir Brahmachari of India’s Council for Scientific and > Industrial Research (CSIR)i, Dr. Christopher Austin from the NIH > Chemical Genomics Center and Dr. Solomon Nwaka of the World Health > Organization. After a short intermission, the session will continue > with talks by Dr. F. Javier Gamo of GlaxoSmithKline and Dr. Alpheus > Bingham from InnoCentive, and end with a panel discussion. > > > > Harper and Munos will also open the afternoon session beginning at > 1:30. Speakers will include Munos, Dr. Zakir Thomas > begin_of_the_skype_highlighting end_of_the_skype_highlighting from > the Open Source Drug Discovery program with CSIR, Dr. Marta Piñeiro- > Núñez of Eli Lilly and Company, Dr. William Scott from IUPUI and Dr. > Sean Ekins of Collaborative Drug Discovery. A final panel discussion > will end the symposium. > > > > Some of the topics to be covered by these leading experts in open- > source drug discovery technology include activities at the NIH to > develop innovative and collaborative later stage drug development > programs, efforts by the WHO to foster novel approaches for research > in neglected diseases, the sharing by GSK of data on over 13,500 > potential anti-malarial compounds, India’s OSDD program activities > involving 3000 people in 74 countries, Lilly’s phenotypic drug > discovery initiative (PD2), distributed drug discovery and > collaborative drug discovery and the various ways in which OSDD can > make it possible for global partnerships across academia, government > and industry to reduce the cost of drug development and make novel > treatments available for the very poor. > > > > Directly following the symposium, there will be a reception and book > signing with Roger F. Jones, author of The Future of the Chemical > Industry, an ACS Symposium Series publication and his fourth and > latest book on industrial, technical, economic and managerial issues > in the chemical industry. > > > > “We are very excited to be sponsors of this unique event at the > National ACS meeting,” states Dr Alan D. Palkowitz, Ph.D., Vice > President, Discovery Chemistry Research & Technologies, Eli Lilly and > Company. “The current pharmaceutical R&D model is being redesigned in > part by this new approach, which is also channeling drug research into > neglected and rare diseases. The speaker line-up represents people in > organizations involved at the forefront of this movement. This > symposium provides a forum for discussion of these early initiatives > and we hope the audience will be inspired to help build on this > foundation.” > > > > -- > http://www.cbclickbank.com/bioinformatics/company.htm > List of the biotech company and address. > > ------------------------------------------------------------------------------------------ > Biofriend Forum > http://www.biofriend.info/ > ============================================= > Meet Biofriend India Team Manager at Linkedin > http://in.linkedin.com/in/satishchauk >
-- Dr U.C.A.Jaleel. Asst Professor in cheminformatics Cheminformatics Division( UGC) Malabar Christian College Calicut University -- http://www.cbclickbank.com/bioinformatics/company.htm List of the biotech company and address. ------------------------------------------------------------------------------------------ Biofriend Forum http://www.biofriend.info/ ============================================= Meet Biofriend India Team Manager at Linkedin http://in.linkedin.com/in/satishchauk
